BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 15865084)

  • 1. Ribavirin in the treatment of hepatitis C.
    Abonyi ME; Lakatos PL
    Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin.
    Hoofnagle JH; Ghany MG; Kleiner DE; Doo E; Heller T; Promrat K; Ong J; Khokhar F; Soza A; Herion D; Park Y; Everhart JE; Liang TJ
    Hepatology; 2003 Jul; 38(1):66-74. PubMed ID: 12829988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3.
    Barreiro P; Martín-Carbonero L; Núñez M; Rivas P; Morente A; Simarro N; Labarga P; González-Lahoz J; Soriano V
    Clin Infect Dis; 2006 Apr; 42(7):1032-9. PubMed ID: 16511772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the treatment of hepatitis C.
    Lawrence SP
    Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
    Antúnez I; Aponte N; Fernández-Carbia A; Rodríguez-Perez F; Toro DH
    P R Health Sci J; 2004 Jun; 23(2 Suppl):57-60. PubMed ID: 16929588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can science meet the challenges of the HCV pandemic: new treatment options for chronic hepatitis C.
    Roehr B
    J Int Assoc Physicians AIDS Care; 1998 Jul; 4(7):24-9. PubMed ID: 11365638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural history of hepatitis C and the impact of anti-viral therapy.
    Boyer N; Marcellin P
    Forum (Genova); 2000; 10(1):4-18. PubMed ID: 10717254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic hepatitis C in patients with persistently normal alanine transaminase levels.
    Shiffman ML; Diago M; Tran A; Pockros P; Reindollar R; Prati D; Rodríguez-Torres M; Lardelli P; Blotner S; Zeuzem S
    Clin Gastroenterol Hepatol; 2006 May; 4(5):645-52. PubMed ID: 16630770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferon-alpha and ribavirin combination therapy for co-infection of hepatitis C virus and human immunodeficiency virus].
    Zheng YH; He Y; Yang X; Gong GZ; Zhou HY; Zhang CY; Zhou W; Huang L; Ding PP; Li H
    Zhonghua Gan Zang Bing Za Zhi; 2005 Oct; 13(10):741-4. PubMed ID: 16248945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acute hepatitis C: response to treatment with interferon-alpha plus ribavirin].
    Vega Palomares R; Planas Vilà R; Durández Lazaro R; Fábregas Puigtió S
    Gastroenterol Hepatol; 2002 Oct; 25(8):483-6. PubMed ID: 12361528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
    Bressler BL; Guindi M; Tomlinson G; Heathcote J
    Hepatology; 2003 Sep; 38(3):639-44. PubMed ID: 12939590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV and HCV co-infection: situation at six French university hospitals in the year 2000.
    Buffet-Janvresse C; Peigue-Lafeuille H; Benichou J; Vabret A; Branger M; Trimoulet P; Goria O; Laurichesse H; Abbed A; Verdon R; Bouvet E; Lafon ME; Dussaix E; Cormerais L; Dupon M; Henquell C; Josse A; Lagoutte P; Lariven S; LeGac S; Riachi G; Verdon R; Vittecoq D;
    J Med Virol; 2003 Jan; 69(1):7-17. PubMed ID: 12436472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin.
    Yalcin K; Degertekin H; Yildiz F; Kilinc N
    J Gastroenterol; 2003; 38(8):796-800. PubMed ID: 14505137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
    Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.